glycine has been researched along with Waldenstrom Macroglobulinemia in 6 studies
Waldenstrom Macroglobulinemia: A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 9.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 5.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Castillo, JJ | 1 |
| Meid, K | 1 |
| Flynn, CA | 1 |
| Chen, J | 1 |
| Demos, MG | 1 |
| Guerrera, ML | 1 |
| Kofides, A | 1 |
| Liu, X | 1 |
| Munshi, M | 1 |
| Tsakmaklis, N | 1 |
| Patterson, CJ | 1 |
| Yang, G | 1 |
| Hunter, Z | 1 |
| Treon, SP | 1 |
| Ma, W | 1 |
| Zhao, J | 1 |
| Zhang, L | 1 |
| Smolewski, P | 1 |
| Rydygier, D | 1 |
| BERLIN, NI | 1 |
| Virella, G | 1 |
| Lopes-Virella, MF | 1 |
| Andersen, BR | 1 |
| Tesar, JT | 1 |
| Schmid, FR | 1 |
| Haisty, WK | 1 |
| Hartz, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia[NCT02400437] | Phase 2 | 26 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The duration of response is measured from the time a participant achieved a response until the date of progression. (NCT02400437)
Timeframe: From the time each participant achieved a response to time of disease progression, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 33 |
Overall response includes the rate of complete response (CR), partial response (PR), minimal response (MR), stabl disease (SD) and progressive disease (PD). Minor response is >25%-50% reduction in serum IgM from baseline. Partial Response is (>50-90% reduction in serum IgM from baseline. Very Good Partial Response is >90% reduction in serum IgM from baseline. Complete Response is resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly. (NCT02400437)
Timeframe: 2 Years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 25 |
To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or >25% reduction in serum IgM from baseline. (NCT02400437)
Timeframe: 2 Years
| Intervention | Participants (Count of Participants) |
|---|---|
| MYD88 Mutated, CXCR4 Wild-type | 11 |
| MYD88 Mutated, CXCR4 Mutated | 14 |
Duration of time from start of treatment to disease progression. Progressive disease is defined as occurring when a >25% increase in serum IgM and an absolute 500mg/dL increase in IgM level occurs from the lowest attained response value, or progression of clinically significant disease related symptoms. (NCT02400437)
Timeframe: From start of treatment to time of disease progression, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 33 |
Duration from start of protocol treatment to time of initiation of new therapy. (NCT02400437)
Timeframe: From start of treatment until the participant begins a new therapy, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 39 |
Duration of time from start of treatment to time of disease progression. (NCT02400437)
Timeframe: From start of treatment to time of disease progression, assessed up to 4 years after treatment start
| Intervention | months (Median) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 33 |
Rate of very good partial response or better in patients treated with IDR. VGPR is defined as a >90% reduction in serum IgM levels from baseline. (NCT02400437)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Ixazomib, Dexamethasone, Rituximab | 5 |
2 reviews available for glycine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Boron Compounds; Dexamethasone; Drugs, Investi | 2019 |
DETERMINATION OF RED BLOOD CELL LIFE SPAN.
Topics: Anemia; Carbon Isotopes; Chromium Isotopes; Erythrocytes; Glycine; Hemoglobins; Hemoglobins, Abnorma | 1964 |
1 trial available for glycine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Topics: Boron Compounds; Dexamethasone; Follow-Up Studies; Glycine; Humans; Myeloid Differentiation Factor 8 | 2020 |
3 other studies available for glycine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boron Compo | 2021 |
Effects of therapeutically useful thiols (DL-penicillamine and alpha-mercaptopropionylglycine) on immunoglobulins.
Topics: Agammaglobulinemia; Blood Viscosity; Chromatography, Gel; Cryoglobulins; Electrophoresis; gamma-Glob | 1970 |
Biological and physical properties of a human m-cryoglobulin and its monomer subunit.
Topics: Alkylation; Binding Sites; Blood Proteins; Carbohydrates; Chemical Precipitation; Complement Fixatio | 1971 |